TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) is expected to report third quarter earnings results, after market close, on Tuesday 10th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.65 per share.
Looking ahead, the full year loss are expected at $ 2.68 per share.
Stock Performance
Shares of TRACON Pharmaceuticals, Inc. traded up $ 0.37 or 7.14 percent on Monday, reaching $ 5.55 with volume of 812.20 thousand shares. TRACON Pharmaceuticals, Inc. has traded high as $ 6.19 and has cracked $ 5.31 on the downward trend
According to the previous trading day, closing price of $ 5.55, representing a 445.26 % increase from the 52 week low of $ 0.95 and a 18.68 % decrease over the 52 week high of $ 6.37.
The company has a market capital of $ 75.95 million and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 17th September 2020, maintained by HC Wainwright at Buy rating, with $ 7.00 target price.
Conference Call
TRACON Pharmaceuticals, Inc. will be hosting a conference call at 4:30 PM eastern time on 10th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.traconpharma.com
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead product candidate is TRC105, an endoglin antibody, which is in randomized Phase III clinical trial for angiosarcoma; Phase I/II clinical trial for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trial for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trial for wet AMD. The company also develops TRC102, a small molecule that is in Phase II clinical trial for mesothelioma, Phase I clinical trial for solid tumors and lung cancer, and Phase I/II clinical trial for solid tumors and lymphomas; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trial for the treatment prostate cancer.
